News
KTRA
--
0.00%
--
Kintara initiates recruitment for VAL-083's study arm in the GBM AGILE trial
Kintara Therapeutics (KTRA) has announced that patient recruitment in the Global Coalition for Adaptive Research (GCAR) Phase 2/3 trial for glioblastoma ((GBM)), has commenced.The company is targeting 150-200 patients with
Seekingalpha · 01/13 14:06
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
, /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that patient recruitment has commenced in the Global Coal...
PR Newswire - PRF · 01/13 13:00
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
PR Newswire · 01/13 13:00
Kazia, Kintara’s gliblastoma candidates to be evaluated GBM AGILE study
The Global Coalition for Adaptive Research ((GCAR)) in collaboration with Kazia ([[KZIA]] -3.4%) and Kintara ([[KTRA]] -1.3%), have announced the activation of Kazia's paxalisib and Kintara's VAL-083 in Glioblastoma trial
Seekingalpha · 01/06 20:09
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial
GCAR, Kazia, and Kintara Announce Commencement of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE
Business Wire · 01/06 18:00
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO will present at the H.C. Wainwright Bioconnect 2021 Virtual ...
PR Newswire - PRF · 01/05 13:00
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
PR Newswire · 01/05 13:00
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2 Annual Glioblastoma Drug Development Virtual Summit ...
PR Newswire - PRF · 12/03/2020 13:30
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2 Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10, 2020 at .
PR Newswire - PRF · 12/03/2020 13:30
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
PR Newswire · 12/03/2020 13:30
KTRA: Year-End Kick-off for GCAR Trial
Zacks Small Cap Research · 12/01/2020 09:47
KTRA: Year-End Kick-off for GCAR Trial
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT First Quarter Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics Inc. (NASDAQ:KTRA) announced first quarter financial and operational results last week in a press release and filed its 10-K with the SEC for its fiscal first quarter ending September 30, 2020. The reporting period included the execution of
Zacks Small Cap Research · 12/01/2020 09:47
KTRA: VAL-083 Poster Updates
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Kintara Therapeutics Inc. (NASDAQ:KTRA) provided an update to their VAL-083 ongoing newly-diagnosed, recurrent and first line glioblastoma (GBM) Phase II trials in two posters present...
Zacks Small Cap Research · 11/30/2020 12:44
KTRA: VAL-083 Poster Updates
Zacks Small Cap Research · 11/30/2020 12:44
Medigus, Aptevo Therapeutics leads healthcare gainers; MeiraGTx Holdings, Kintara Therapeutics among major losers
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%, Berkeley Lights (BLI) -10%, Kazia Therapeutics (KZIA) -8%, Immutep (IMMP) -7%.
Seekingalpha · 11/19/2020 16:00
Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme
Kintara Therapeutics (KTRA) announces interim data from its two Phase 2 trials of VAL-083, the Company's lead compound for the treatment of glioblastoma multiforme ((GBM)).In newly-diagnosed receiving VAL-083 as adjuvant therapy, 27
Seekingalpha · 11/19/2020 13:49
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
, /PRNewswire/ -- According to the American Cancer Society, the number of new acute myeloid leukemia cases is estimated to continue to grow in the U.S. due to a number of factors. The rising prevalence of acute myeloid leukemia and unmet needs of the pati...
PR Newswire - PRF · 11/19/2020 13:30
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
, /PRNewswire/ -- According to the American Cancer Society, the number of new acute myeloid leukemia cases is estimated to continue to grow in the U.S. due to a number of factors. The rising prevalence of acute myeloid leukemia and unmet needs of the patients have resulted in an increased focus on the development of new drugs. New drug approvals for the acute myeloid leukemia treatment, are expected to drive the growth of global acute myeloid leukemia treatment market. In fact, a in iHealthcareAnalyist said that the global market for acute myeloid leukemia expected to reach by 2025, growing at CAGR 19.6% over the forecast period, driven by introduction of high-priced products and strong pipeline of upcoming drugs. During the forecast period, the marketed drugs, pipeline drugs and others are predicted to contribute 55%, 35%, and 10% market share of the global AML market, respectively. Another from Reports And Data had even higher projections saying that the global Acute Myeloid Leukemia Therapeutics market is forecasted to grow at a rate of 13.1% and will reach in 2027. Active biotech and pharma companies in the markets this week include (NASDAQ: MBRX), (NASDAQ: KTRA), (NYSE: MRK),  (NASDAQ: KZIA), (NASDAQ: OMER).
PR Newswire - PRF · 11/19/2020 13:30
LB, YY, BERY and NKLA among premarket gainers
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept
Seekingalpha · 11/19/2020 13:29
Kintara Therapeutics Reports 10 Months Progression-Free Survival In Newly-Diagnosed MGMT-Unmethylated GBM From Ongoing MD Anderson Cancer Center Phase 2 Study
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study SAN DIEGO, Nov. 19, 2020 /PRNewswire/
Benzinga · 11/19/2020 13:06
Webull provides a variety of real-time KTRA stock news. You can receive the latest news about Kintara Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
More